Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia

Haematologica

Volumn 99, Issue 4, 2014, Pages 788-793

  Efficace, Fabio ^a   Rosti, Gianantonio ^b   Aaronson, Neil ^c   Cottone, Francesco ^a   Angelucci, Emanuele ^d   Molica, Stefano ^e   Vignetti, Marco ^a   Mandelli, Franco ^a   Baccarani, Michele ^b  

^a Data Center and Health Outcomes Research Unit   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d Ospedale Oncologico A Businco   (Italy)

^e PUGLIESE CIACCIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; DIARRHEA; DISEASE SEVERITY; EDEMA; FATIGUE; FEMALE; HEADACHE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; PHYSICIAN; QUESTIONNAIRE; SCORING SYSTEM; SKIN DISEASE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; SELF REPORT; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; HEALTH STATUS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PHYSICIANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUESTIONNAIRES; SELF REPORT; YOUNG ADULT;

EID: 84897373052     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.093724     Document Type: Article

References (31)

1. Kris MG, Benowitz SI, Adams S, Diller L, Ganz P, Kahlenberg MS, et al. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2010;28(36):5327-47.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
3. Gambacorti-Passerini C, Antolini L, Mahon F-X, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103(7):553-61.
4. Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118(17):4554-60.
5. Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013;21(4):1097-103.
6. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-17.
7. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2251-9.
8. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-70.
9. Marin D. Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2012:115-21.
10. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-51. Erratum in: Lancet Oncol. 2011;12(11):989.
11. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123-9.
12. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004;22 (17):3485-90.
13. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624-32.
14. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903-9.
15. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865-9.
16. National Cancer Institute. U.S. Department of Health and Human Services. Division of Cancer Control and Population Sciences, Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). http://outcomes.cancer. gov/tools/pro-ctcae_fact_ sheet.pdf (accessed may 28, 2012).
17. Efficace F, Breccia M, Baccarani M, Alimena G, Lambertenghi Deliliers G, Specchia G, et al. Development and feasibility of a patientreported symptom checklist for chronic myeloid leukemia patients [abstract]. Haematologica 2010;95(Suppl 2):S189.
18. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-83.
19. Bjorner J, Fayers P, Idler E. Self-rated Health, in Assessing Quality of Life in Clinical Trials. 2nd ed. Fayers P, Hays R, editors. New York: Oxford University Press; 2005. p. 309-23.
20. Suarez-Almazor ME, Conner-Spady B, Kendall CJ, Russell AS, Skeith K. Lack of congruence in the ratings of patients' health status by patients and their physicians. Med Decis Making. 2001;21(2):113-21.
21. Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Lambertenghi Deliliers G, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013;27(7): 1511-9.
22. National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology. Cancer-related fatigue. V.1.2013.
23. Pinilla-Ibarz J, Cortes J, Mauro MJ. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer. 2011;117(4): 688-97.
24. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28(14):2381-8.
25. Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22): 5401-11.
26. Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35(5):626-30.
27. Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22(4):714-24.
28. Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-oflife assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002;288(23):3027-34.
29. Hilarius DL, Kloeg PH, Gundy CM, Aaronson NK. Use of health-related qualityof-life assessments in daily clinical oncology nursing practice: a community hospital-based intervention study. Cancer. 2008;113(3):628-37.
30. Williams LA, Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013;122(5):641-7.
31. Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res. 2013 Sep 13. [Epub ahead of print]